MarketPeel
Insider Trading Intelligence
DH

David C. Hastings

TRVI
CHIEF FINANCIAL OFFICER · TREVI THERAPEUTICS, INC. · CIK 0001237401
FILING MIX · LIFETIME92%/8%
BUYS
23
SELLS
2
TOTAL VALUE
$895.9K
COMPANIES
3
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
743,675
AVG SELL PX
$2.99
TRADE KIND
SHOWING 25 / 25
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by David C. Hastings, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+50.00%+7.24%+0.99%+6.25%+6.25%
14d2+0.00%+10.92%+1.33%+9.60%+9.60%
30d2+0.00%+7.08%-0.60%+7.68%+7.68%
60d2+50.00%+1.01%-5.25%+6.26%+6.26%
90d2+0.00%+8.54%-1.80%+10.34%+10.34%
180d2+50.00%+28.90%+8.66%+20.24%+20.24%
1y2+0.00%+27.70%+18.84%+8.86%+8.86%
2y2(1 pending)+0.00%+84.45%+42.90%+41.55%+41.55%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
Not enough transaction history to chart holdings.
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 23 buys / 2 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
2,8752,875Jun 26, 2026Jun 30, 2026View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
2,87511,522Jun 26, 2026Jun 30, 2026View →
TRVI
TREVI THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
375,000375,000Jan 8, 2026Jan 12, 2026View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
23,00069,183Jun 26, 2025Jun 30, 2025View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
23,00023,000Jun 26, 2025Jun 30, 2025View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
90,100249,824Feb 14, 2025Feb 19, 2025View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
365,800365,800Feb 14, 2025Feb 19, 2025View →
ABUS
ARBUTUS BIOPHARMA CORP
SALE10b5-1
10b5-1 plan
22,183$3.28$72.8K159,724Feb 4, 2025Feb 5, 2025View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
23,00023,000Jun 20, 2024Jun 21, 2024View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
23,00046,183Jun 20, 2024Jun 21, 2024View →
ABUS
ARBUTUS BIOPHARMA CORP
SALE10b5-1
10b5-1 plan
9,593$2.31$22.2K181,907Feb 2, 2024Feb 5, 2024View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
450,000450,000Feb 1, 2024Feb 5, 2024View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
112,500191,500Feb 1, 2024Feb 5, 2024View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
10,00010,000Jun 15, 2023Jun 20, 2023View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
10,00023,183Jun 15, 2023Jun 23, 2023View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
316,000316,000Feb 1, 2023Feb 3, 2023View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
79,00079,000Feb 1, 2023Feb 3, 2023View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
10,00010,000Jun 17, 2022Jun 22, 2022View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
10,00013,183Jun 17, 2022Jun 22, 2022View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
285,000$2.81$800.9K285,000Jan 20, 2022Jan 20, 2022View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
10,00010,000Jun 16, 2021Jun 21, 2021View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
250,000250,000Feb 13, 2021Feb 17, 2021View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
55,00055,000Jul 6, 2020Mar 31, 2021View →
SCYX
SCYNEXIS INC
PURCHASEGRANT
Stock grant
45,00045,000Jul 6, 2020Jul 8, 2020View →
ABUS
ARBUTUS BIOPHARMA CORP
PURCHASEGRANT
Stock grant
100,000100,000Feb 17, 2020Feb 19, 2020View →
Other insiders · TRVI
Loading peer insiders…
About this filer
CIK 0001237401
ROLE
Chief Financial Officer
PRIMARY
TRVI
COMPANIES
3
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001237401DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback